The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis

Journal of Infection

Volumn 52, Issue 5, 2006, Pages

  Jain, Lakshmi R ^a   Denning, David W ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

Aspergilloma; Complication; Fumigatus; Lobectomy; Resistance

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN E; ITRACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; EYE TOXICITY; FLUSHING; HEADACHE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION CONTROL; LIVER TOXICITY; LUNG ASPERGILLOSIS; NEUROTOXICITY; NONHUMAN; PARESTHESIA; PHOTOSENSITIVITY DISORDER; QUANTITATIVE ANALYSIS; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT; SYMPTOM; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CHRONIC DISEASE; FEMALE; HUMANS; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; PYRIMIDINES; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 33645931389     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2005.08.022     Document Type: Article

References (19)

1. Denning D.W., Riniotis K., Dobrashian R., and Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature and review. Clin Infect Dis 37 Suppl 3 (2003) 265-280
2. Campbell J.H., Winter J.H., Richardson M.D., Shankland G.S., and Banham S.W. Treatment of pulmonary aspergillosis with itraconazole. Thorax 46 (1991) 839-841
3. Saraceno J.L., Phelps D.T., Futerfas R., et al. Chronic necrotizing pulmonary aspergillosis: approach to management. Chest 112 (1997) 541-548
4. Tsubura E. Multicenter clinical trial of itraconazole in the treatment of pulmonary aspergilloma. Pulmonary Aspergilloma Study Group. Kekkaku 72 (1997) 557-564
5. el Oakley R., Petrou M., and Goldstraw P. Indications and outcome of surgery for pulmonary aspergilloma. Thorax 52 (1997) 813-815
6. Lee S.H., Lee B.J., Jung do Y., Kim J.H., Sohn D.S., Shin J.W., et al. Clinical manifestations and treatment outcomes of pulmonary aspergilloma. Korean J Intern Med 19 (2004) 38-42
7. Denning D.W. Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 7 (2001) 25-31
8. Keevil B., Newman S., Lockhart S., Moore C.B., Howard S., and Denning H.W. Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry. Ther Drug Monit 26 (2004) 650-657
9. Gomez-Lopez A., Garcia-Effron G., Mellado E., Monzon A., Rodriguez-Tudela J.L., and Cuenca-Estrella M. In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 47 (2003) 3085-3088
10. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New Engl J Med 347 (2002) 408-415
11. Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti Infect Ther 2 (2004) 485-497
12. Denning D.W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., et al. The efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34 (2002) 563-571
13. Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005;43(Suppl 1) S207-38.
14. Gefter W.B., Weingrad T.R., Epstein D.M., Ochs R.H., and Miller W.T. 'Semi-invasive' pulmonary aspergillosis: a new look at the spectrum of Aspergillus infections of the lung. Radiology 140 (1981) 313-321
15. Binder R.E., Faling J.L., Pugatch R.D., Mahasaen C., and Snider G.L. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine 61 (1982) 109-123
16. Crosdale D., Poulton K., Ollier W., Thomson W., and Denning D.W. Mannose binding lectin gene polymorphisms as a susceptibility factor for chronic necrotising pulmonary aspergillosis. J Infect Dis 184 (2001) 653-656
17. Caras W.E., and Pluss J.L. Chronic necrotizing pulmonary aspergillosis: pathologic outcome after itraconazole therapy. Mayo Clin Proc 71 (1996) 25-30
18. Schiraldi F.S., Gramegna G., De Rosa C., Lo Cicero S., Capone P., Ferrarese M., et al. Chronic pulmonary aspergillosis: current classification and therapy. Curr Opin Investig Drugs 4 (2003) 186-191
19. Tucker R.M., Haq Y., Denning D.W., and Stevens D.A. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 26 (1990) 561-566